Driven by the potential to treat the root cause of diseases, including rare clinical conditions and those that were previously deemed incurable, the gene therapies pipeline is growing, and the market anticipated to witness substantial growth, till 2030
Success of approved gene therapies has resulted in a surge in interest of biopharmaceutical developers in this rapidly evolving domain. Presently, the ability of gene therapies to treat diverse disease indications is considered among the most prominent drivers of this market. In addition, promising clinical results of pipeline candidates are anticipated to draw in more investments to support product development initiatives.
To order this 720+ page report, which features 220+ figures and 375+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/gene-therapies-market/268.html
Key Market Insights
Around 800 gene therapies are currently being developed across different stages
Apart from 10 approved products, most of the aforementioned therapies (65%) are in the early stages of development (discovery / preclinical), while the rest are being evaluated in clinical trials. It is worth mentioning that more than 40% of clinical stage candidates are intended for the treatment of oncological disorders.
Over 65% of innovator companies focused on gene therapy development, are based in North America
Interestingly, more than 75 players based in the same region, are start-ups, while over 35 are mid-sized players, and 10 are large and very large firms. Since the majority of gene therapy developers are headquartered in the US, it is considered a key RD hub for such advanced therapy medicinal products.
There are 400+ registered gene therapy focused clinical trials, worldwide
Clinical research activity, in terms of number of trials registered, is reported to have increased at a CAGR of 12% during the period 2015-2020. Of the total number of trials, close to 25% have already been completed, and 35% claim to be actively recruiting.
USD 25.4 billion has been invested by both private and public investors, since 2015
So far, a significant proportion of the capital raised has been through secondary offerings (USD 12.9 billion). On the other hand, around USD 5 billion was invested by venture capital investors, representing 20% of the total amount.
Close to 20,000 patents have been filed / published related to gene therapies, since 2016
Around 30% of the total number of applications were related to gene editing-based therapies, while the remaining were associated with gene therapies. Further, majority of the patent assignees were industry players, however, the contribution of non-industry players in the overall patent filing activity has increased considerably (CAGR of 16%), over the past few years.
There have been several mergers and acquisitions in this market during the period 2015-2019
In fact, MA activity is reported to have increased at a CAGR of more than 40%. Key drivers of the acquisitions mentioned in the report include, therapeutic area expansion, access to a novel technology / platform, drug class consolidation and drug class expansion.
To request a sample copy / brochure of this report, please visit this - https://www.rootsanalysis.com/reports/268/request-sample.html
The report features inputs from eminent industry stakeholders, according to whom, gene therapies exhibit the potential to become a promising alternative for the treatment of genetic disorders. The report includes detailed transcripts of discussions held with the following experts:
- Adam Rogers (CEO, Hemera Biosciences)
- Al Hawkins (CEO, Milo Biotechnology)
- Buel Dan Rodgers (Founder CEO, AAVogen)
- Christopher Reinhard (CEO Chairman, Gene Therapeutics (previously known as Cardium Therapeutics))
- Michael Triplett (ex-CEO, Myonexus Therapeutics)
- Robert Jan Lamers (ex-CEO, Arthrogen)
- Ryo Kubota (CEO, Chairman President, Acucela)
- Tom Wilton (ex-CBO, LogicBio Therapeutics)
- Jeffrey Hung (CCO, Vigene Biosciences)
- Cedric Szpirer (Executive Scientific Director, Delphi Genetics)
- Marco Schmeer (Project Manager) and Tatjana Buchholz (ex-Marketing Manager, PlasmidFactory)
- Molly Cameron (Corporate Communications Manager, Orchard Therapeutics)
The research includes brief profiles of key players (listed below) engaged in the development of gene therapies; each profile features an overview of the therapy, current development status, clinical trials and its results (if available), target indication, route of administration, and recent developments (if available).
- Abeona Therapeutics
- bluebird bio
- Castle Creek Biosciences
- CG Oncology
- Freeline Therapeutics
- Inovio Pharmaceuticals
- Kolon TissueGene
- Krystal Biotech
- Neurophth Therapeutics
- OncoSec Immunotherapies
- Orchard Therapeutics
- Sangamo Therapeutics
- Spark Therapeutics
- uniQure Biopharma
- VBL Therapeutics
For additional details, please visit https://www.rootsanalysis.com/reports/view_document/gene-therapies-market/268.html or email firstname.lastname@example.org
You may also be interested in the following titles:
- Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market (4th Edition), 2021-2030
- Global T-Cell (CAR-T, TCR, and TIL) Therapies Market (5th Edition), 2020-2030
- Oncolytic Virus Therapy Market: Pipeline Review, Developer Landscape and Competitive Insights, 2020-2030
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at email@example.com
+1 (415) 800 3415
Facebook - https://www.facebook.com/RootsAnalysis
Twitter - https://twitter.com/RootsAnalysis